SPARC and colorectal cancer: To conclude, the findings of our current study demonstrate that: (1) SPARC is frequently aberrantly methylated in colorectal cancers, (2) specific methylated CpG sites have been identified that are present within the SPARC promoter of colorectal cancers, and (3) higher expression of SPARC can be achieved with 5-Aza-2′deoxycytidine, leading to improved sensitivity to chemotherapy.